175 related articles for article (PubMed ID: 26833481)
1. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
[TBL] [Abstract][Full Text] [Related]
2. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
[TBL] [Abstract][Full Text] [Related]
3. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
4. Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Watanabe A; Yamamoto K; Ioroi T; Hirata S; Harada K; Miyake H; Fujisawa M; Nakagawa T; Yano I; Hirai M
Biol Pharm Bull; 2017; 40(4):458-464. PubMed ID: 28381801
[TBL] [Abstract][Full Text] [Related]
5.
Yamamoto K; Ioroi T; Shinomiya K; Yoshida A; Harada K; Fujisawa M; Omura T; Ikemi Y; Nakagawa S; Yonezawa A; Ogawa O; Matsubara K; Iwamoto T; Nishikawa K; Hayashi S; Tohara D; Murakami Y; Motoshima T; Jono H; Yano I
Oncol Res; 2022 May; 29(1):11-23. PubMed ID: 35016744
[TBL] [Abstract][Full Text] [Related]
6. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
[TBL] [Abstract][Full Text] [Related]
7. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
8. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.
Ivanyi P; Winkler T; Grosshennig A; Reuter C; Merseburger AS; Ganser A; Grünwald V
World J Urol; 2010 Jun; 28(3):311-7. PubMed ID: 20443009
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
[TBL] [Abstract][Full Text] [Related]
12. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Numakura K; Tsuchiya N; Kagaya H; Takahashi M; Tsuruta H; Inoue T; Narita S; Huang M; Satoh S; Niioka T; Miura M; Habuchi T
Anticancer Drugs; 2017 Jan; 28(1):97-103. PubMed ID: 27564227
[TBL] [Abstract][Full Text] [Related]
14. STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.
Zhao L; Zhang Q; Luan X; Huang X; Zhao S; Zhao H
Int J Clin Exp Pathol; 2015; 8(2):2033-8. PubMed ID: 25973100
[TBL] [Abstract][Full Text] [Related]
15. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
16. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
17. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Cebrián A; Gómez Del Pulgar T; Méndez-Vidal MJ; Gonzálvez ML; Lainez N; Castellano D; García-Carbonero I; Esteban E; Sáez MI; Villatoro R; Suárez C; Carrato A; Munárriz-Ferrándiz J; Basterrechea L; García-Alonso M; González-Larriba JL; Perez-Valderrama B; Cruz-Jurado J; González Del Alba A; Moreno F; Reynés G; Rodríguez-Remírez M; Boni V; Mahillo-Fernández I; Martin Y; Viqueira A; García-Foncillas J
Sci Rep; 2017 Jan; 7():41371. PubMed ID: 28117391
[TBL] [Abstract][Full Text] [Related]
18. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.
Sławińska M; Zabłotna M; Gleń J; Lakomy J; Nowicki RJ; Sobjanek M
Arch Dermatol Res; 2019 Nov; 311(9):697-704. PubMed ID: 31342143
[TBL] [Abstract][Full Text] [Related]
19. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population.
Qin C; Cao Q; Li P; Ju X; Wang M; Chen J; Wu Y; Meng X; Zhu J; Zhang Z; Lu Q; Yin C
PLoS One; 2012; 7(1):e28829. PubMed ID: 22295057
[TBL] [Abstract][Full Text] [Related]
20. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?
Masuda A; Kamai T; Abe H; Arai K; Yoshida K
Biomed Res; 2009 Jun; 30(3):171-6. PubMed ID: 19574718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
